| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0165-6147(00)89032-X |
| P698 | PubMed publication ID | 7667897 |
| P2093 | author name string | Kenakin T | |
| P2860 | cites work | Differential signal transduction by five splice variants of the PACAP receptor | Q28566746 |
| Competitive antagonists discriminate between NK2 tachykinin receptor subtypes | Q33933966 | ||
| Are receptors promiscuous? Intrinsic efficacy as a transduction phenomenon | Q39268976 | ||
| Agonist-receptor efficacy I: mechanisms of efficacy and receptor promiscuity | Q40469880 | ||
| Membrane organization in G-protein mechanisms. | Q40705142 | ||
| Agonist-specific coupling of a cloned Drosophila octopamine/tyramine receptor to multiple second messenger systems | Q40791205 | ||
| Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor. | Q41379008 | ||
| Evidence for the presence of a septide-sensitive tachykinin receptor in the circular muscle of the guinea-pig ileum | Q46936145 | ||
| Selective activation of inhibitory G-protein alpha-subunits by partial agonists of the human 5-HT1A receptor | Q72357768 | ||
| On the definition of efficacy | Q72545167 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 232-238 | |
| P577 | publication date | 1995-07-01 | |
| P1433 | published in | Trends in Pharmacological Sciences | Q2451474 |
| P1476 | title | Agonist-receptor efficacy. II. Agonist trafficking of receptor signals | |
| P478 | volume | 16 |
| Q35210020 | 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass? |
| Q34946743 | (4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs. |
| Q37417284 | 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion |
| Q41533296 | 5-HT receptor classification and nomenclature: towards a harmonization with the human genome |
| Q34284419 | 6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment |
| Q47145368 | A Complementary Scale of Biased Agonism for Agonists with Differing Maximal Responses |
| Q34540545 | A Pluridimensional View of Biased Agonism |
| Q41902757 | A Practical Guide to Approaching Biased Agonism at G Protein Coupled Receptors |
| Q64938892 | A Receptor Model With Binding Affinity, Activation Efficacy, and Signal Amplification Parameters for Complex Fractional Response Versus Occupancy Data. |
| Q42097755 | A comparison of agonist-specific coupling of cloned human alpha(2)-adrenoceptor subtypes |
| Q47070511 | A comparison of the signalling properties of two tyramine receptors from Drosophila |
| Q42046971 | A functional assay for G-protein-coupled receptors using stably transformed insect tissue culture cell lines |
| Q85008509 | A holistic view of GPCR signaling |
| Q35531857 | A novel method for analyzing extremely biased agonism at G protein-coupled receptors |
| Q28369773 | A novel phenylaminotetralin (PAT) recognizes histamine H1 receptors and stimulates dopamine synthesis in vivo in rat brain |
| Q28728741 | A simple method for quantifying functional selectivity and agonist bias |
| Q98280979 | A single unified model for fitting simple to complex receptor response data |
| Q41633163 | A three-state receptor model of agonist action |
| Q36082162 | A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling |
| Q34274685 | Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at μ- and δ-Opioid Receptors |
| Q42035013 | Activation of constitutive 5-hydroxytryptamine(1B) receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its G(o)alpha protein interactions |
| Q37416009 | Activation of muscarinic acetylcholine receptors via their allosteric binding sites. |
| Q40657735 | Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines |
| Q48344779 | Activation of various subtypes of G-protein alpha subunits by partial agonists of the adenosine A1 receptor |
| Q37598488 | Adapter proteins and promoter regulation of the angiotensin AT2 receptor--implications for cardiac pathophysiology |
| Q44720869 | Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro |
| Q28235776 | Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats |
| Q44583796 | Agonist function of the neurokinin receptor antagonist, [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, in monocytes |
| Q40803951 | Agonist regulation of D(2) dopamine receptor/G protein interaction. Evidence for agonist selection of G protein subtype |
| Q40125857 | Agonist selective modulation of tyrosine hydroxylase expression by cannabinoid ligands in a murine neuroblastoma cell line |
| Q28361199 | Agonist trafficking of G(i/o)-mediated alpha(2A)-adrenoceptor responses in HEL 92.1.7 cells |
| Q42638818 | Agonist-dependent modulation of G-protein coupling and transduction of 5-HT1A receptors in rat dorsal raphe nucleus |
| Q42710489 | Agonist-directed trafficking explaining the difference between response pattern of naratriptan and sumatriptan in rabbit common carotid artery |
| Q24323261 | Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells |
| Q35875524 | Agonist-selective effects of opioid receptor ligands on cytosolic calcium concentration in rat striatal neurons |
| Q33604101 | Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications |
| Q48952749 | Agonist-specific coupling of a cloned Drosophila melanogaster D1-like dopamine receptor to multiple second messenger pathways by synthetic agonists |
| Q44400220 | Agonist-specific coupling of a cloned human α1A-adrenoceptor to different second messenger pathways |
| Q39832616 | Agonist-specific patterns of beta 2-adrenoceptor responses in human airway cells during prolonged exposure |
| Q44582560 | Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor |
| Q53082766 | Allosteric modulation as a unifying mechanism for receptor function and regulation. |
| Q38327838 | Amino acid-stimulated Ca2+ oscillations produced by the Ca2+-sensing receptor are mediated by a phospholipase C/inositol 1,4,5-trisphosphate-independent pathway that requires G12, Rho, filamin-A, and the actin cytoskeleton |
| Q35720141 | An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations. |
| Q41869522 | An investigation of whether agonist-selective receptor conformations occur with respect to M2 and M4 muscarinic acetylcholine receptor signalling via Gi/o and Gs proteins |
| Q42025205 | Arachidonic acid release mediated by OX1 orexin receptors |
| Q33966353 | Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. |
| Q44209133 | Bell-shaped curves for prostaglandin-induced modulation of adenylate cyclase: two mutually opposing effects |
| Q48649680 | Beta-adrenoceptors in the tree shrew brain. I. Distribution and characterization of [125I]iodocyanopindolol binding sites |
| Q41863995 | Biased agonism |
| Q37368610 | Biased agonism as a mechanism for differential signaling by chemokine receptors. |
| Q26823970 | Biased and g protein-independent signaling of chemokine receptors |
| Q39256591 | Biased signaling at neural melanocortin receptors in regulation of energy homeostasis |
| Q37948862 | Biased signalling and allosteric machines: new vistas and challenges for drug discovery |
| Q47231111 | Biased signalling: from simple switches to allosteric microprocessors |
| Q36790136 | Binding between a distal C-terminus fragment of cannabinoid receptor 1 and arrestin-2. |
| Q46307475 | Binding profile of the novel 5-HT1B/1D receptor antagonist, [3H]GR 125,743, in guinea-pig brain: a comparison with [3H]5-carboxamidotryptamine |
| Q35153734 | Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors |
| Q48593958 | Biological activities of N6,C8-disubstituted adenosine derivatives as partial agonists at rat brain adenosine A1 receptors |
| Q40809869 | Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism |
| Q35171170 | CODA-RET reveals functional selectivity as a result of GPCR heteromerization |
| Q37553926 | Cellular assays as portals to seven-transmembrane receptor-based drug discovery |
| Q45232096 | Characterisation of AmphiAmR4, an amphioxus (Branchiostoma floridae) α₂-adrenergic-like G-protein-coupled receptor |
| Q35964527 | Characterisation of Signalling by the Endogenous GPER1 (GPR30) Receptor in an Embryonic Mouse Hippocampal Cell Line (mHippoE-18). |
| Q42020948 | Cloning of an octopamine/tyramine receptor and plasticity of its expression as a function of adult sexual maturation in the male moth Agrotis ipsilon |
| Q53583903 | Collateral efficacy as a pharmacological problem applied to new drug discovery. |
| Q73930962 | Comparative effects of neurotensin, neurotensin(8-13) and [D-Tyr(11)]neurotensin applied into the ventral tegmental area on extracellular dopamine in the rat prefrontal cortex and nucleus accumbens |
| Q71656443 | Comparison of 5-HT4 receptors in guinea-pig colon and rat oesophagus: effects of novel agonists and antagonists |
| Q44343648 | Comparison of cyclic delta-opioid peptides with non-peptide delta-agonist spiroindanyloxymorphone (SIOM) using the message-address concept: a molecular modeling study |
| Q42524236 | Conserved helix 7 tyrosine acts as a multistate conformational switch in the 5HT2C receptor. Identification of a novel "locked-on" phenotype and double revertant mutations. |
| Q34506086 | Constitutive G(i2)-dependent activation of adenylyl cyclase type II by the 5-HT1A receptor. Inhibition by anxiolytic partial agonists |
| Q42951315 | Constitutive activity of cannabinoid-2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242. |
| Q70841350 | Constitutive activity of the M1-M4 subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists |
| Q34310093 | Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. |
| Q42443514 | Constitutive precoupling to G(i) and increased agonist potency in the alpha(2B)-adrenoceptor |
| Q44318898 | Contractile actions of imidazoline alpha-adrenoceptor agonists and effects of noncompetitive alpha1-adrenoceptor antagonists in human vas deferens |
| Q35201084 | Corticotropin-releasing factor and urocortin I activate CREB through functionally selective Gβγ signaling in hippocampal pyramidal neurons |
| Q42084998 | Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation |
| Q39341454 | Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. |
| Q42937057 | Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. |
| Q42522479 | Decreased G-protein coupling of serotonin 5-HT(1A) receptors in the brain of 5-HT(1B) knockout mouse |
| Q34365195 | Defect in MAPK signaling as a cause for monogenic obesity caused by inactivating mutations in the melanocortin-4 receptor gene |
| Q35198039 | Delineation of a conserved arrestin-biased signaling repertoire in vivo. |
| Q34659433 | Descending control of pain |
| Q37397259 | Determination of adenosine A1 receptor agonist and antagonist pharmacology using Saccharomyces cerevisiae: implications for ligand screening and functional selectivity |
| Q41698372 | Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry |
| Q44578132 | Different pharmacological properties of two equipotent antagonists (clozapine and rauwolscine) for 5-HT2B receptors in rat stomach fundus |
| Q43172881 | Differential activation of the epithelial and smooth muscle NK1 receptors by synthetic tachykinin agonists in guinea-pig trachea |
| Q40584252 | Differential chemokine activation of CC chemokine receptor 1-regulated pathways: ligand selective activation of Galpha 14-coupled pathways |
| Q39906615 | Differential effects of AGS3 expression on D(2L) dopamine receptor-mediated adenylyl cyclase signaling |
| Q77375698 | Dissecting intracellular signaling pathways with membrane-permeable peptides |
| Q34760546 | Dissociations in the effects of β2-adrenergic receptor agonists on cAMP formation and superoxide production in human neutrophils: support for the concept of functional selectivity |
| Q34099978 | Diverse signalling by 5-hydroxytryptamine (5-HT) receptors |
| Q38214620 | Diversity and Bias through Receptor-Receptor Interactions in GPCR Heteroreceptor Complexes. Focus on Examples from Dopamine D2 Receptor Heteromerization. |
| Q82029300 | Dopamine receptor pharmacology |
| Q34011162 | Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride |
| Q35573424 | Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation |
| Q73312122 | Elimination of palmitoylation sites in the human dopamine D1 receptor does not affect receptor-G protein interaction |
| Q37803251 | Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. |
| Q38200338 | Employing novel animal models in the design of clinically efficacious GPCR ligands |
| Q74562609 | Endothelin ET(B) receptors show different binding profiles in intact cells and cell membrane preparations |
| Q35851621 | Ensemble of G protein-coupled receptor active states |
| Q42092237 | Epitope-tagged receptor knock-in mice reveal that differential desensitization of alpha2-adrenergic responses is because of ligand-selective internalization |
| Q39660780 | Evaluation of Cannabinoid Receptor 2 and Metabotropic Glutamate Receptor 1 Functional Responses Using a Cell Impedance–Based Technology |
| Q46240693 | Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles |
| Q42521477 | Evidence for protean agonism of RX 831003 at alpha 2A-adrenoceptors by co-expression with different G alpha protein subunits |
| Q38819497 | Exploiting agonist biased signaling of chemokines to target cancer. |
| Q34660378 | Exploring a role for heteromerization in GPCR signalling specificity |
| Q34451544 | Fitting the complexity of GPCRs modulation into simple hypotheses of ligand design |
| Q35999789 | Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism. |
| Q48656806 | Functional Selectivity and Biased Receptor Signaling |
| Q28143318 | Functional coupling of G proteins to endothelin receptors is ligand and receptor subtype specific |
| Q40663313 | Functional coupling of the human dopamine D2 receptor with G alpha i1, G alpha i2, G alpha i3 and G alpha o G proteins: evidence for agonist regulation of G protein selectivity |
| Q38017279 | Functional selectivity in GPCR heterocomplexes. |
| Q38017282 | Functional signaling biases in G protein-coupled receptors: Game Theory and receptor dynamics. |
| Q37337832 | Functionally biased signalling properties of 7TM receptors - opportunities for drug development for the ghrelin receptor |
| Q47860164 | G protein-coupled receptors. II. Mechanism of agonist activation |
| Q28350001 | G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype |
| Q41914206 | G-protein activation by putative antagonists at mutant Thr373Lys alpha2A adrenergic receptors |
| Q28576185 | G-protein oestrogen receptor 1: trials and tribulations of a membrane oestrogen receptor |
| Q52761888 | GPCR-mediated rapid, non-genomic actions of steroids: comparisons between DmDopEcR and GPER1 (GPR30). |
| Q27005640 | Gaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessors |
| Q40842125 | Gbetagamma subunit combinations differentially modulate receptor and effector coupling in vivo |
| Q90148445 | Genetic code expansion and photocross-linking identify different β-arrestin binding modes to the angiotensin II type 1 receptor |
| Q33714695 | Genetic deletion of p90 ribosomal S6 kinase 2 alters patterns of 5-hydroxytryptamine 2A serotonin receptor functional selectivity |
| Q39414464 | Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways |
| Q28374171 | High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action |
| Q36734824 | Identification of a Novel Gnao-Mediated Alternate Olfactory Signaling Pathway in Murine OSNs |
| Q42450308 | Identification of a conserved switch residue responsible for selective constitutive activation of the beta2-adrenergic receptor |
| Q45099209 | Identification of amino acid residues that direct differential ligand selectivity of mammalian and nonmammalian V1a type receptors for arginine vasopressin and vasotocin. Insights into molecular coevolution of V1a type receptors and their ligands |
| Q34376764 | Identification of novel functionally selective κ-opioid receptor scaffolds |
| Q38199134 | Identifying ligand-specific signalling within biased responses: focus on δ opioid receptor ligands |
| Q39515353 | Impact of fusion to Gα(i2) and co-expression with RGS proteins on pharmacological properties of human cannabinoid receptors CB₁R and CB₂R. |
| Q44350218 | Influence of Gz and Gi2 transducer proteins in the affinity of opioid agonists to mu receptors. |
| Q47888201 | Influence of beta-adrenoceptor agonists on the pulmonary circulation. Effects of a beta3-adrenoceptor antagonist, SR 59230A. |
| Q36279906 | Insect octopamine receptors: a new classification scheme based on studies of cloned Drosophila G-protein coupled receptors |
| Q56648606 | Insights into signaling from the β2-adrenergic receptor structure |
| Q42048502 | Interaction of the D2short dopamine receptor with G proteins: analysis of receptor/G protein selectivity |
| Q38064157 | Interactions of the GnRH receptor with heterotrimeric G proteins |
| Q44446940 | Interactions of xylazine and detomidine with alpha2-adrenoceptors in brain tissue from cattle, swine and rats |
| Q40474801 | Internalization and Src activity regulate the time course of ERK activation by delta opioid receptor ligands. |
| Q53503547 | Interrogating 7TM receptors: does texture in the question yield greater texture in the answer? |
| Q39213738 | Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast |
| Q37834732 | Irving Page Lecture: 5-HT(2A) serotonin receptor biology: interacting proteins, kinases and paradoxical regulation |
| Q37568616 | Is GPR55 an anandamide receptor? |
| Q41501062 | Is promiscuity of G protein interaction an issue in the classification of receptors? |
| Q35546017 | Isoproterenol acts as a biased agonist of the alpha-1A-adrenoceptor that selectively activates the MAPK/ERK pathway. |
| Q30484494 | LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor |
| Q39580127 | Label-free optical biosensor with microfluidics for sensing ligand-directed functional selectivity on trafficking of thrombin receptor |
| Q38200427 | Ligand bias prevents class equality among beta-blockers. |
| Q38014954 | Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors |
| Q34055218 | Ligand-induced modulation of the free-energy landscape of G protein-coupled receptors explored by adaptive biasing techniques |
| Q35181787 | Ligand-selective receptor conformations revisited: the promise and the problem |
| Q77408413 | Loss of activation of Gs but not Gi following expression of an alpha2A-adrenoceptor-Gi1alpha fusion protein |
| Q51499124 | Measurement of Receptor Signaling Bias. |
| Q74028262 | Measurement of agonist efficacy using an alpha2A-adrenoceptor-Gi1alpha fusion protein |
| Q34466267 | Mechanisms of citric acid-induced bronchoconstriction |
| Q39972489 | Metabolic responses to BRL37344 and clenbuterol in soleus muscle and C2C12 cells via different atypical pharmacologies and beta2-adrenoceptor mechanisms |
| Q37610141 | Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery. |
| Q31031906 | Modelling of promiscuous receptor-Gi/Gs-protein coupling and effector response |
| Q31561672 | Modulation of 5-HT(1A) receptor activation by its interaction with wild-type and mutant g(alphai3) proteins |
| Q48148688 | Modulation of 5-HT1A receptor signalling by point-mutation of cysteine351 in the rat Galpha(o) protein |
| Q38295552 | Monitoring G-protein-coupled receptor signaling with DNA microarrays and real-time polymerase chain reaction |
| Q35044317 | Mouse beta 3a- and beta 3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways |
| Q46899031 | Multiple conformations of 5-HT2A and 5-HT 2C receptors in rat brain: an autoradiographic study with [125I](±)DOI. |
| Q38101499 | Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology |
| Q52564801 | Mutations remote from the human gonadotropin-releasing hormone (GnRH) receptor-binding sites specifically increase binding affinity for GnRH II but not GnRH I: evidence for ligand-selective, receptor-active conformations. |
| Q30828627 | Myr+-Gi2 alpha and Go alpha subunits restore the efficacy of opioids, clonidine and neurotensin giving rise to antinociception in G-protein knock-down mice. |
| Q36899819 | Neoclerodanes as atypical opioid receptor ligands |
| Q34354034 | Neurokinin B and the hypothalamic regulation of reproduction |
| Q34358365 | New CCK2 agonists confirming the heterogeneity of CCK2 receptors: characterisation of BBL454. |
| Q91612119 | New Insights in Cannabinoid Receptor Structure and Signaling |
| Q37136050 | New aspects of G-protein-coupled receptor signalling and regulation |
| Q36303814 | New concepts in drug discovery: collateral efficacy and permissive antagonism |
| Q38044984 | New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. |
| Q37822833 | New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma |
| Q28575089 | Niacin stimulates adiponectin secretion through the GPR109A receptor |
| Q28298974 | Nicotinic acid receptor agonists differentially activate downstream effectors |
| Q44087155 | Nitric oxide signalling by selective beta(2)-adrenoceptor stimulation prevents ACh-induced inhibition of beta(2)-stimulated Ca(2+) current in cat atrial myocytes |
| Q48779366 | Nomenclature and classification of transmitter receptors: an integrated approach |
| Q42656342 | Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells |
| Q73094041 | Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors |
| Q73198117 | Noradrenaline-induced pigment aggregating response of melanophores in normal, denervated and reinnervated cichlid skin |
| Q36788564 | Novel aspects of G-protein-coupled receptor signalling--different ways to achieve specificity. |
| Q36812968 | Octopamine-mediated neuromodulation of insect senses |
| Q34075509 | Odorant-specific modes of signaling in mammalian olfaction |
| Q61814337 | Opposing Actions of Adrenocorticotropic Hormone and Glucocorticoids on UCP1-Mediated Respiration in Brown Adipocytes |
| Q37784750 | Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs |
| Q44485831 | Partial adenosine A(1) receptor agonists inhibit sarin-induced epileptiform activity in the hippocampal slice |
| Q44413518 | Pharmacological characterization of putative β1-β2-adrenergic receptor heterodimers |
| Q36911200 | Pharmacological onomastics: what's in a name? |
| Q26822470 | Physiology of the orexinergic/hypocretinergic system: a revisit in 2012 |
| Q34174259 | Plasmon resonance studies of agonist/antagonist binding to the human delta-opioid receptor: new structural insights into receptor-ligand interactions |
| Q37322612 | Posttranslation modification of G protein-coupled receptor in relationship to biased agonism |
| Q38585840 | Practical guide for calculating and representing biased signaling by GPCR ligands: A stepwise approach |
| Q35140840 | Predicting therapeutic value in the lead optimization phase of drug discovery |
| Q37974268 | Probing heterotrimeric G protein activation: applications to biased ligands. |
| Q78339333 | Protean behavior by agonists: agonist-directed trafficking of receptor signaling |
| Q28142282 | Qualitative and quantitative assessment of relative agonist efficacy |
| Q35188090 | Quantifying ligand bias at seven-transmembrane receptors. |
| Q38571588 | RGS proteins destroy spare receptors: Effects of GPCR-interacting proteins and signal deamplification on measurements of GPCR agonist potency |
| Q42825199 | RNA editing of the human serotonin 5-HT2C receptor alters receptor-mediated activation of G13 protein |
| Q28359232 | RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity |
| Q38324252 | Rapid, nongenomic responses to ecdysteroids and catecholamines mediated by a novel Drosophila G-protein-coupled receptor. |
| Q35693323 | Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology |
| Q38077226 | Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function. |
| Q28069545 | Recent advances in understanding the extracellular calcium-sensing receptor |
| Q35996747 | Receptor conformations involved in dopamine D(2L) receptor functional selectivity induced by selected transmembrane-5 serine mutations |
| Q48198217 | Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange |
| Q31968670 | Role of G-protein availability in differential signaling by alpha 2-adrenoceptors |
| Q35041990 | Role of nitric oxide and septide-insensitive NK(1) receptors in bronchoconstriction induced by aerosolised neurokinin A in guinea-pigs |
| Q46264487 | Roles of PKA, PI3K, and cPLA2 in the NO-mediated negative inotropic effect of beta2-adrenoceptor agonists in guinea pig right papillary muscles. |
| Q42616337 | Rotation and immediate-early gene expression in rats treated with the atypical D1 dopamine agonist SKF 83822. |
| Q21145330 | Scalable rule-based modelling of allosteric proteins and biochemical networks |
| Q41089062 | Selective inhibition of adenylyl cyclase by octopamine via a human cloned alpha 2A-adrenoceptor |
| Q53436889 | Serotonin receptor and dendritic plasticity in the spinal cord mediated by chronic serotonergic pharmacotherapy combined with exercise following complete SCI in the adult rat. |
| Q36647024 | Serotonin receptor signaling and regulation via β-arrestins |
| Q34402623 | Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo |
| Q33890786 | Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery |
| Q24644854 | Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist |
| Q39170901 | Signaling bias in drug discovery |
| Q37245459 | Signaling by G-protein-coupled receptor (GPCR): studies on the GnRH receptor |
| Q38081692 | Signalling bias in new drug discovery: detection, quantification and therapeutic impact. |
| Q28343257 | Signalling by CXC-chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPgammaS binding induced by IL-8 and GROalpha |
| Q38358522 | Site-directed mutagenesis studies on the Drosophila octopamine/tyramine receptor |
| Q42447334 | Somatostatin sst5 inhibition of receptor mediated regeneration of rat aortic vascular smooth muscle cells |
| Q35921807 | Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy |
| Q28289039 | Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors |
| Q36628927 | Structure-function of alpha1-adrenergic receptors |
| Q38567235 | Superagonism at G protein-coupled receptors and beyond |
| Q42316573 | Systematic errors in detecting biased agonism: Analysis of current methods and development of a new model-free approach. |
| Q46572669 | Tachykinin NK-1 receptor probed with constrained analogues of substance P. |
| Q37230848 | Targeting V1A-vasopressin receptors with [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies. |
| Q33985759 | Teaching old receptors new tricks: biasing seven-transmembrane receptors |
| Q34171396 | The GPCR membrane receptor, DopEcR, mediates the actions of both dopamine and ecdysone to control sex pheromone perception in an insect |
| Q35964839 | The Janus faces of adrenoceptors: factors controlling the coupling of adrenoceptors to multiple signal transduction pathways. |
| Q41148501 | The P2Y purinoceptor in rat brain microvascular endothelial cells couple to inhibition of adenylate cyclase |
| Q48036335 | The activation of G-protein gated inwardly rectifying K+ channels by a cloned Drosophila melanogaster neuropeptide F-like receptor |
| Q35911754 | The atypical antipsychotics clozapine and olanzapine promote down-regulation and display functional selectivity at human 5-HT7 receptors. |
| Q34245210 | The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. |
| Q41500995 | The characterization and classification of neurotransmitter receptors |
| Q43193479 | The effect of site-directed mutagenesis of two transmembrane serine residues on agonist-specific coupling of a cloned human alpha2A-adrenoceptor to adenylyl cyclase |
| Q47689706 | The elusive nature of intrinsic efficacy |
| Q38341649 | The expression of a cloned Drosophila octopamine/tyramine receptor in Xenopus oocytes |
| Q41021887 | The intrinsic activity of (-)-3-PPP vis-à-vis prolactin-suppressing dopamine D2 receptors in transfected GH4C1 cells is dependent on which secretagogue that is used to provoke prolactin release |
| Q38617373 | The mass action equation in pharmacology |
| Q35202929 | The neurobiology and control of anxious states |
| Q37131419 | The origins of diversity and specificity in g protein-coupled receptor signaling |
| Q45261068 | The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism |
| Q34402658 | The potential for selective pharmacological therapies through biased receptor signaling |
| Q38178842 | The role of serotonin in memory: interactions with neurotransmitters and downstream signaling |
| Q42801633 | The two NK-1 binding sites correspond to distinct, independent, and non-interconvertible receptor conformational states as confirmed by plasmon-waveguide resonance spectroscopy. |
| Q34088801 | The year in G protein-coupled receptor research |
| Q24628602 | Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor |
| Q74537571 | Three-state and two-state models |
| Q41501018 | To what extent can binding studies allow the quantification of affinity and efficacy? |
| Q40629393 | Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex |
| Q38959067 | Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update |
| Q39819177 | VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist |
| Q42832267 | [D-Arg1,D-Phe5,D-Trp7,9,Leu11]Substance P acts as a biased agonist toward neuropeptide and chemokine receptors |
| Q53107798 | [G-protein-coupled receptors plasticity and signalling]. |
| Q57566304 | beta-Adrenoreceptor antagonists reduce cancer cell proliferation, invasion, and migration |
| Q41091060 | beta2-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists |
| Q42439448 | h5-HT(1B) receptor-mediated constitutive Galphai3-protein activation in stably transfected Chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5-HT |
| Q59805371 | β-Arrestin Based Receptor Signaling Paradigms: Potential Therapeutic Targets for Complex Age-Related Disorders |
| Q36211207 | β-Blockers have differential effects on the murine asthma phenotype |
| Q45306194 | β2-adrenoceptor agonists can both stimulate and inhibit glucose uptake in mouse soleus muscle through ligand-directed signalling |
Search more.